Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.46 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13003704 | 0.81 | HSP90AA1 (0.44) | HSP90AA1HSP90B1NPC1RAB9AESR1 | |
| SCHEMBL2243603 | 0.81 | NPC1 (0.40) | NPC1RAB9AESR1ESR2JAK2 | |
| SCHEMBL2181393 | 0.80 | ESR1 (0.41) | HSP90AA1NPC1RAB9AESR1ESR2 | |
| SCHEMBL720364 | 0.80 | ESR1 (0.48) | HSP90AA1HSP90B1NPC1RAB9AESR1 | |
| SCHEMBL2249696 | 0.80 | PDGFRB (0.47) | NPC1RAB9AESR1ESR2PDGFRB | |
| SCHEMBL2246755 | 0.80 | ESR1 (0.41) | NPC1RAB9AESR1ESR2JAK2 | |
| SCHEMBL12706723 | 0.78 | HSP90AA1 (0.47) | HSP90AA1HSP90B1 | |
| SCHEMBL2243486 | 0.78 | NPC1 (0.40) | NPC1RAB9AESR1ESR2JAK2 | |
| SCHEMBL12413626 | 0.78 | NPC1 (0.40) | HSP90AA1HSP90B1NPC1RAB9AESR1 | |
| SCHEMBL2246205 | 0.77 | ESR1 (0.42) | NPC1RAB9AESR1ESR2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| EP-2252613-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM, LLC (BM) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009105717-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009105717-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | HSP90AA1 1856/4885HSP90B1 2054/4885NPC1 376/4885 |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | GPR119, GLP1R, GIPR | HSP90AA1 2957/4885HSP90B1 2574/4885NPC1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.